Show simple item record

dc.contributor.authorAzuar, Armira
dc.contributor.authorZhao, Lili
dc.contributor.authorHei, Tsui Ting
dc.contributor.authorNevagi, Reshma J
dc.contributor.authorBartlett, Stacey
dc.contributor.authorHussein, Waleed M
dc.contributor.authorKhalil, Zeinab G
dc.contributor.authorCapon, Robert J
dc.contributor.authorToth, Istvan
dc.contributor.authorSkwarczynski, Mariusz
dc.date.accessioned2020-04-17T01:57:31Z
dc.date.available2020-04-17T01:57:31Z
dc.date.issued2019
dc.identifier.issn1948-5875
dc.identifier.doi10.1021/acsmedchemlett.9b00239
dc.identifier.urihttp://hdl.handle.net/10072/393177
dc.description.abstractPeptide-based subunit vaccines require an immunostimulant (adjuvant) and/or delivery system to protect the antigenic peptide from degradation and induce the desired immunity. Currently available adjuvants are either too toxic for human use (experimental adjuvants) or they are limited for use in particular vaccines or licensed countries (commercial adjuvants). Therefore, there is an immediate need for novel adjuvants that are both safe and effective. Herein, we assessed the ability of cholic acid (a major bile acid) as a nontoxic, biodegradable, human-derived, potent vaccine delivery system. An antigenic peptide derived from Group A Streptococcus was conjugated to hydrophobic cholic acid via solid phase peptide synthesis to produce lipopeptide that self-assembled into rod-like nanoparticles under aqueous conditions. Following intranasal immunization in mice, this lipopeptide was capable of inducing the production of opsonic epitope-specific antibodies on its own and in liposomal formulation. The cholic acid-based conjugate induced significantly stronger humoral immune responses than cholera toxin-based adjuvant. Thus, we demonstrated, for the first time, capability of the human-derived lipid to act as a built-in immunoadjuvant for vaccines.
dc.description.peerreviewedYes
dc.languageen
dc.publisherAmerican Chemical Society (ACS)
dc.relation.ispartofpagefrom1253
dc.relation.ispartofpageto1259
dc.relation.ispartofissue9
dc.relation.ispartofjournalACS Medicinal Chemistry Letters
dc.relation.ispartofvolume10
dc.subject.fieldofresearchMedicinal and Biomolecular Chemistry
dc.subject.fieldofresearchOrganic Chemistry
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode0304
dc.subject.fieldofresearchcode0305
dc.subject.fieldofresearchcode1115
dc.titleCholic Acid-based Delivery System for Vaccine Candidates against Group A Streptococcus
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationAzuar, A; Zhao, L; Hei, TT; Nevagi, RJ; Bartlett, S; Hussein, WM; Khalil, ZG; Capon, RJ; Toth, I; Skwarczynski, M, Cholic Acid-based Delivery System for Vaccine Candidates against Group A Streptococcus, ACS Medicinal Chemistry Letters, 2019, 10 (9), pp. 1253-1259
dc.date.updated2020-04-17T01:56:45Z
gro.hasfulltextNo Full Text
gro.griffith.authorNevagi, Reshma J.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record